RT Journal Article
SR Electronic
T1 Risk of drug-induced interstitial lung disease in hospitalised patients: a nested case–control study
JF Thorax
JO Thorax
FD BMJ Publishing Group Ltd and British Thoracic Society
SP 1193
OP 1199
DO 10.1136/thoraxjnl-2020-215824
VO 76
IS 12
A1 Taisuke Jo
A1 Nobuaki Michihata
A1 Hayato Yamana
A1 Kojiro Morita
A1 Miho Ishimaru
A1 Yasuhiro Yamauchi
A1 Wakae Hasegawa
A1 Hirokazu Urushiyama
A1 Kazuaki Uda
A1 Hiroki Matsui
A1 Kiyohide Fushimi
A1 Hideo Yasunaga
A1 Takahide Nagase
YR 2021
UL http://thorax.bmj.com/content/76/12/1193.abstract
AB Introduction Information on drug-induced interstitial lung disease (DILD) is limited due to its low incidence. This study investigated the frequencies of drug categories with potential risk in patients developing DILD during hospitalisation and analysed the risk of developing DILD associated with each of these drugs.Methods Using a Japanese national inpatient database, we identified patients without interstitial pneumonia on admission who developed DILD and required corticosteroid therapy during hospitalisation from July 2010 to March 2016. We conducted a nested case–control study; four controls from the entire non-DILD patient cohort were matched to each DILD case on age, sex, main diagnosis, admission year and hospital. We defined 42 classified categories of drugs with 216 generic names as drugs with potential risk of DILD, and we identified the use of these drugs during hospitalisation for each patient. We analysed the association between each drug category and DILD development using conditional logistic regression analyses.Results We retrospectively identified 2342 patients who developed DILD. After one-to-four case–control matching, 1541 case patients were matched with 5677 control patients. Six drug categories were significantly associated with the increased occurrence of DILD. These included epidermal growth factor receptor inhibitors (OR: 16.84, 95% CI 9.32 to 30.41) and class III antiarrhythmic drugs (OR: 7.01, 95% CI 3.86 to 12.73). Statins were associated with reduced risk of DILD (OR: 0.68, 95% CI 0.50 to 0.92).Conclusions We demonstrated significant associations between various drug categories and DILD. Our findings provide useful information on drug categories with potential risk to help physicians prevent and treat DILD.Data are available upon reasonable request. Data cannot be made publicly available for ethical reasons as the data are patient data. Data are available to interested researchers upon reasonable request to the corresponding author, pending ethical approval.